SENTINEL LYMPH node (SLN) biopsy has become
|
|
- Laurence Wheeler
- 5 years ago
- Views:
Transcription
1 COMMENTARY Sentinel Lymph Node Biopsy for Melanoma: Controversy Despite Widespread Agreement By Kelly M. McMasters, Douglas S. Reintgen, Merrick I. Ross, Jeffrey E. Gershenwald, Michael J. Edwards, Arthur Sober, Neil Fenske, Frank Glass, Charles M. Balch, and Daniel G. Coit Abstract: Although sentinel lymph node (SLN) biopsy for melanoma has been adopted throughout the United States and abroad as a standard method of determining the pathologic status of the regional lymph nodes, some controversy still exists regarding the validity and utility of this procedure. SLN biopsy is a minimally invasive procedure, performed on an outpatient basis at the time of wide local excision of the melanoma, with little morbidity. Numerous studies have documented the accuracy of this procedure for identifying nodal metastases. There are four major reasons to perform SLN biopsy. First, SLN biopsy improves the accuracy of staging and provides valuable SENTINEL LYMPH node (SLN) biopsy has become widely accepted as a minimally invasive method of staging the regional lymph nodes for melanoma. Recently, it has been suggested that this procedure is highly controversial 1,2 ; however, this is a controversy about which there is widespread agreement. SLN biopsy has been adopted as the standard method of nodal staging for melanoma at nearly every major medical center in the United States. Furthermore, the World Health Organization has issued a statement indicating that SLN biopsy should be considered standard of care for patients with melanoma. 3 We believe that there are four major reasons to perform SLN biopsy. All of them involve the critically important issue of accurate staging. First, SLN biopsy improves the accuracy of staging and provides valuable prognostic information for patients and physicians to guide subsequent treatment decisions. Second, SLN biopsy facilitates early therapeutic lymph node dissection for those patients with nodal metastases. Third, SLN biopsy identifies patients who are candidates for adjuvant therapy with interferon alfa-2b. Fourth, SLN biopsy identifies homogeneous patient populations for entry onto clinical trials of novel adjuvant therapy agents. PROGNOSTIC INFORMATION FOR PATIENTS AND PHYSICIANS Morton et al 4 first demonstrated the feasibility and accuracy of SLN biopsy for nodal staging of patients with melanoma. The low false-negative rate of SLN biopsy for melanoma has been confirmed in additional studies from other institutions, not only by comparing SLN biopsy prognostic information for patients and physicians to guide subsequent treatment decisions. Second, SLN biopsy facilitates early therapeutic lymph node dissection for those patients with nodal metastases. Third, SLN biopsy identifies patients who are candidates for adjuvant therapy with interferon alfa-2b. Fourth, SLN biopsy identifies homogeneous patient populations for entry onto clinical trials of novel adjuvant therapy agents. Overall, the benefit of accurate nodal staging obtained by SLN biopsy far outweighs the risks and has important implications for patient management. J Clin Oncol 19: by American Society of Clinical Oncology. results to completion lymphadenectomy specimens, but also by long-term follow-up to determine recurrence in undissected nodal basins after a negative SLN biopsy SLN status is the most important predictor of survival of patients with melanoma. In fact, in the report by Gershenwald et al, 14 the hazard ratio for survival associated with a positive SLN was 6.53, much greater than that for any other prognostic factor (Table 1). No combination of prognostic factors of the primary tumor can provide this prognostic information. This nodal staging information serves two purposes. First, it identifies a population of patients with a relatively favorable prognosis for which adjuvant therapy may not be necessary. Second, it identifies a high-risk population of patients who may benefit from additional From the Department of Surgery, University of Louisville, James Graham Brown Cancer Center; Center for Advanced Surgical Technologies at Norton Healthcare; and the Alliant Community Trust Fund, Louisville, KY; University of South Florida, Moffitt Cancer Center, Tampa, FL; The American Society of Clinical Oncology, Alexandria, VA; The Johns Hopkins University, Baltimore, MD; The University of Texas M.D. Anderson Cancer Center, Houston, TX; Harvard University, Boston, MA; and Memorial Sloan-Kettering Center, New York, NY. Submitted November 15, 2000; accepted March 5, Address reprint requests to Kelly M. McMasters, MD, PhD, University of Louisville-James Graham Brown Cancer Center, 529 S Jackson St, Louisville, KY 40202; kelly.mcmasters@ nortonhealthcare.org by American Society of Clinical Oncology X/01/ Journal of Clinical Oncology, Vol 19, No 11 (June 1), 2001: pp
2 2852 Table 1. Prognostic Factors Relative to Disease-Specific Survival* Disease-Specific Survival Prognostic Factor Hazard Ratio 95% CI P Age Sex Tumor thickness Clark level III Axial location Ulceration SLN status *Table adapted with permission from Gershenwald et al. 14 therapy. This information is immediately worthwhile in guiding patients to make appropriate choices regarding additional treatment and has important implications for patient follow-up. It has been suggested that, unless SLN biopsy can be shown to improve overall survival for patients with melanoma, it is not valuable. 1,2 An ongoing study, the Multicenter Selective Lymphadenectomy Trial (MSLT) by Morton et al, 15 will address the impact of SLN on survival. While we await the results of this study, we believe that even if SLN biopsy in and of itself does not improve survival, it has inherent value and should be continued until or unless another less invasive staging test with similar predictive value is developed. SLN biopsy is a diagnostic staging test. We do not impose the burden of therapeutic efficacy on other diagnostic staging tests in oncology, including computed tomography scan, magnetic resonance imaging, positron emission tomography scan, or for that matter, axillary lymph node dissection for breast cancer. SLN biopsy is minimally invasive, is performed at the same time as the wide local excision of the primary melanoma, and has been shown to be cost effective and less morbid compared with elective lymph node dissection. 16,17 That is not to say that this test should be over-utilized. SLN biopsy is appropriate for patients with a significant risk of nodal metastasis, including those with melanomas 1.0 mm Breslow thickness or greater SLN biopsy for melanomas less than 1.0 mm Breslow thickness with poor prognostic features (eg, ulceration and Clark s level IV) may be appropriate and requires further investigation. IDENTIFICATION OF PATIENTS WHO MAY BENEFIT FROM EARLY THERAPEUTIC LYMPH NODE DISSECTION Before the advent of SLN biopsy, the pathologic nodal status of patients with melanoma was known only after elective lymph node dissection. However, four prospective randomized trials have failed to demonstrate an overall survival benefit for patients who undergo elective lymph node dissection This has led to the common misconception that lymphadenectomy offers no therapeutic benefit for patients with melanoma. However, the important distinction between elective and therapeutic lymph node dissection is often overlooked or obscured. Lymph node dissection is curative for some patients with nodal metastases. A substantial and reproducible fraction of stage III melanoma patients is cured by lymphadenectomy, and this was true long before any adjuvant therapy was available. Furthermore, in patients with positive nodes, tumor burden as measured by the number of positive nodes has been consistently the best predictor of outcome. Therefore, it makes intuitive sense that early removal of lymph nodes should be better than waiting until the patient develops multiple positive nodes with bulky, palpable disease. Why, then, has there been no survival benefit in the trials of elective lymph node dissection? The answer has to do with the fact that with elective lymph node dissection, the majority of patients do not have cancer in the lymph nodes. As an example, consider the Intergroup Melanoma Trial of elective lymph node dissection. In that study, patients with intermediate thickness melanoma were randomized to observation versus elective lymph node dissection. 21,22 The hypothesis was that early lymph node dissection while the patients had subclinical nodal metastasis would improve survival compared with waiting until the patients developed palpable nodal metastases. Overall, 20% of the patients in the observation arm developed positive lymph nodes. Therefore, 80% of the patients had no potential or real therapeutic benefit from early lymph node dissection. Let s consider that elective lymph node dissection imparts a survival advantage similar to other forms of adjuvant therapy, approximately 25% to 50% reduction in the relative risk of death. This is similar to the magnitude of benefit of adjuvant therapy in breast cancer, colon cancer, and so on. Because elective lymph node dissection could only potentially benefit the patients who have cancer in the lymph nodes, at best one quarter to one half of the 20% of patients with positive nodes, or 5% to 10% of patients overall, could be expected to be cured as a result of elective lymph node dissection. Any survival benefit in favor of elective lymph node dissection in randomized trials is diluted by the majority of patients with negative nodes. None of the prospective trials had adequate statistical power to detect this small benefit of elective lymph node dissection in the overall patient population studied. In fact, the 10-year follow-up results that have recently been published for the Intergroup Melanoma Trial demonstrate a 4% overall survival advantage in favor of elective lymph node dissection, although this did not reach statistical significance. 21,22 However, certain prospectively stratified
3 2853 Table 2. Subgroup Analysis of the Intergroup Melanoma Surgical Trial* Subgroup 10-Year Survival (%) P Reduction in Risk of Death (%) Absolute Difference Relative Difference Nonulcerated melanoma Nodal observation 77 ELND Breslow thickness 1.0 to 2.0 mm Nodal observation 80 ELND Extremity melanoma Nodal observation 78 ELND All patients Nodal observation 73 ELND Abbreviation: ELND, elective lymph node dissection. *Table adapted with permission from Balch et al. 21 subgroups of patients, most notably those with nonulcerated melanomas, did benefit from elective lymph node dissection. The magnitude of the benefit in these subgroups of patients was equivalent to that which we would expect based on the above calculations (Table 2). Although retrospective subgroup analysis of clinical trials is always subject to criticism, it is important to point out that patients in this study were prospectively stratified by tumor thickness, anatomic site, and ulceration, and these analyses were planned during the design of the trial. Another crucial piece of evidence regarding the value of early lymph node dissection versus delayed dissection for palpable disease is derived from the World Health Organization Programme 14 Trial of elective lymph node dissection for patients with truncal melanomas. 20 Overall, there was no difference in survival for the two randomized arms (nodal observation v elective lymph node dissection). However, when the survival of the patients with positive lymph nodes, either detected histologically at elective lymph node dissection or by palpation in the observation arm is evaluated, quite a different picture emerges. The overall survival of patients with nodal micrometastases removed at elective lymph node dissection was significantly greater than that of patients who underwent lymphadenectomy for palpable lymph nodes in the observation arm (48% v 27% 5-year survival, respectively, P.04). 20 This difference is significant both statistically and, more important, clinically, despite the relatively small numbers of patients in each subgroup. Therefore, if occult micrometastatic disease can be accurately identified, the data from the Intergroup Melanoma Trial and the World Health Organization Programme 14 trial suggest that early therapeutic lymph node dissection may improve survival. Certainly there is no evidence that patients who undergo delayed lymph node dissection at the time of palpable recurrence have a better prognosis than those who undergo lymphadenectomy when they have microscopic nodal metastases. Therefore, the available evidence suggests that early therapeutic lymph node dissection for microscopic nodal disease may be superior to delayed lymph node dissection once the patients develop palpable nodal disease. 23,24 The problem with elective lymph node dissection is that the procedure is applied indiscriminately to all patients who have clinically negative lymph nodes. Therefore, the majority of patients (without nodal metastases) are subjected to the morbidity of lymphadenectomy without any therapeutic benefit. The ideal situation would be to identify the patients with positive lymph nodes for therapeutic lymph node dissection and spare the rest the need for complete lymph node dissection. This is the advantage of SLN biopsy. When SLN biopsy is performed for patients with melanomas 1.0 mm Breslow thickness, 20% or more will be found to have positive SLNs when careful pathologic analysis is performed Therefore, at least 20% of patients are identified as candidates for additional therapy, which includes therapeutic lymph node dissection. Importantly, patients harboring occult metastatic disease are offered an early therapeutic lymph node dissection, not an elective lymph node dissection. The 80% of patients who have negative SLN are spared the need for lymph node dissection and have undergone a procedure that amounts to little more than a lymph node biopsy performed on an outpatient basis at the time of the wide local excision of the melanoma. IDENTIFICATION OF PATIENTS WHO ARE CANDIDATES FOR ADJUVANT INTERFERON ALFA-2B THERAPY Interferon alfa-2b therapy has been approved by the Food and Drug Administration for adjuvant therapy of high-risk melanoma patients. The vast majority of these high-risk melanoma patients are those with positive lymph nodes. This indication for interferon alfa-2b is based on the the Eastern Cooperative Oncology Group Trial E1684, which demonstrated a disease-free and overall survival benefit for treatment with interferon. 25 However, a follow-up study, E1690, confirmed a disease-free survival benefit, but did not demonstrate an overall survival benefit for patients treated with high-dose interferon alfa-2b. 26 This has generated some controversy regarding the overall benefit of interferon alfa-2b therapy for adjuvant treatment of high-risk melanoma. Part of the explanation for a lack of an overall
4 2854 survival benefit in the E1690 study for high-dose interferon is related to the fact that the observation group had substantially better overall survival than the patients in the observation group in the E1684 study. However, in the E1690 study there was somewhat of a cross-over effect; patients in the observation group in the E1690 study were more likely to receive interferon alfa-2b and other salvage therapies than patients in the interferon-treated group (J. Kirkwood, unpublished data). How can the results of E1684 and E1690 be reconciled? Both studies concluded that high-dose interferon imparts a significant disease-free survival advantage; however, an overall survival advantage was demonstrated only in E1684. Therefore, it is clear that high-dose interferon alfa-2b has activity against melanoma. The advantages in terms of disease-free survival are not disputed. The impact on overall survival remains to be clearly defined. To add further support for adjuvant high-dose interferon alfa-2b therapy, the results of the Eastern Cooperative Oncology Group study E1694 have been presented recently (J. Kirkwood, unpublished data). In this study, 774 high-risk melanoma patients were randomized to receive adjuvant high-dose interferon alfa-2b versus a GM2 ganglioside vaccine. The study was stopped early by the data-monitoring committee based on a planned interim analysis that showed superiority of interferon alfa-2b in terms of both disease-free and overall survival. This study adds important new evidence confirming a beneficial impact of high-dose interferon alfa-2b in melanoma. The goal that lies ahead is to identify the patient populations that benefit most from this therapy. IDENTIFICATION OF HOMOGENEOUS PATIENT POPULATIONS FOR CLINICAL TRIALS OF ADJUVANT THERAPY A significant concern regarding the E1684 and E1690 studies is that very heterogeneous patient populations were studied. The vast majority of patients had palpable nodal disease either synchronous with the primary tumor or recurrent at some time after the primary tumor had been previously excised. Very few patients (12% in E1684% and 11% in E1690) had microscopically positive lymph nodes. These studies were performed before the wide-spread acceptance of SLN biopsy for nodal staging. Whereas, in E1684, pathologic nodal staging by elective lymph node dissection was required, only a few patients in the E1690 study who were staged as T4N0 actually underwent nodal staging with SLN biopsy. As SLN biopsy has become a standard practice in most major medical centers throughout the country, few patients with bulky palpable nodal disease are seen any longer, suggesting that the spectrum of stage III melanoma has changed. The vast majority of stage III patients are now represented by those patients who have microscopically positive nodes detected at SLN biopsy, most frequently a single positive sentinel node. Therefore, the patients with stage III disease currently identified by SLN biopsy represent a significantly different population than that studied in E1684 and E1690. The heterogeneity of the patients entered onto these two studies certainly confounds the interpretation of the results. Therefore, one of the major goals of SLN biopsy is to identify homogeneously staged patient populations for entry onto clinical trials. Only by entry of patients with similar prognoses will meaningful interpretation of adjuvant therapy results be possible. As a result of a major effort on the part of the American Joint Committee on Cancer Melanoma Task Force, major changes in the staging system for melanoma have been proposed. 27,28 These new changes incorporate several important independent prognostic factors that were not taken into account in these two trials. For instance, the number of positive lymph nodes was not a stratification criterion in E1684, although it is now known to be an important prognostic factor. 27,28 Furthermore, it is now known that tumor ulceration is such an important independent prognostic factor that it may be used to upstage patients in each T category of the new American Joint Committee on Cancer staging system. 27,28 Not only is ulceration an important prognostic factor for patients with node-negative melanoma, but it retains its prognostic significance for patients with positive lymph nodes. Therefore, a relatively minor imbalance in ulceration between treatment arms could result in significant differences in survival. Ulceration was not a stratification factor in either E1684 or E1690. This underscores the importance of stratifying patients in clinical trials not only by Breslow thickness, but also by the number of positive lymph nodes and the presence of ulceration. In conclusion, SLN biopsy is a diagnostic staging test to determine the pathologic status of the regional lymph nodes and accurately identifies the presence of nodal metastasis. The presence of a positive SLN is the single most important prognostic factor in determining the likelihood of survival. As such, patients should be offered the option of SLN biopsy, when appropriate, to determine the status of the regional lymph nodes. This provides the opportunity for early therapeutic lymph node dissection, for which there is evidence of benefit in node-positive patients. Furthermore, those patients identified with positive SLNs are then eligible for adjuvant therapy with interferon alfa-2b, which is still the only Food and Drug Administration approved adjuvant therapy for melanoma and is consid-
5 2855 ered by many to be the standard of care and the reference treatment against which all other adjuvant therapies should be compared. The value of SLN biopsy for identifying homogeneous patient populations for entry into clinical trials of novel adjuvant agents cannot be underestimated. Only by identifying populations of patients with similar prognosis will we be likely to develop more effective adjuvant therapies. 1. Otley CC, Zitelli JA: Review of sentinel lymph node biopsy and systemic interferon for melanoma: Promising but investigational modalities. Dermatol Surg : Thomas JM, Patocskai EJ: The argument against sentinel node biopsy for malignant melanoma: Its use should be confined to patients in clinical trials. BMJ 321:3-4, WHO declares lymphatic mapping to be the standard of care for melanoma. Oncology 13:288, Morton DL, Wen DR, Wong JH, et al: Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 127: , Morton DL, Wen DR, Foshag LJ, et al: Intraoperative lymphatic mapping and selective cervical lymphadenectomy for early-stage melanoma of the head and neck. J Clin Oncol 11: , Ross MI, Reintgen D, Balch CM: Selective lymphadenectomy: Emerging role for lymphatic mapping and sentinel node biopsy in the management of early stage melanoma. Semin Surg Oncol 9: , Reintgen D, Cruse CW, Wells K, et al: The orderly progression of melanoma nodal metastases. Ann Surg 220: , Miliotes G, Albertini J, Berman C, et al: The tumor biology of melanoma nodal metastases. Am Surg 62:81-88, Gershenwald JE, Colome MI, Lee JE, et al: Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol 16: , Albertini, JJ, Cruse CW, Rapaport D, et al: Intraoperative radiolymphoscintigraphy improves sentinel lymph node identification for patients with melanoma. Ann Surg 223: , Essner R, Bostick PJ, Glass EC, et al: Standardized probedirected sentinel node dissection in melanoma. Surgery 127: Gershenwald JE, Tseng CH, Thompson W, et al: Improved sentinel lymph node localization in patients with primary melanoma with the use of radiolabeled colloid. Surgery 124: , Essner R, Conforti A, Kelley MC, et al: Efficacy of lymphatic mapping, sentinel lymphadenectomy, and selective complete lymph node dissection as a therapeutic procedure for early-stage melanoma. Ann Surg Oncol 6: , Gershenwald JE, Thompson W, Mansfield PF, et al: Multiinstitutional melanoma lymphatic mapping experience: The prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 17: , Morton DL, Thompson JF, Essner R, et al: Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: A multicenter trial Multicenter REFERENCES Selective Lymphadenectomy Trial Group. Ann Surg 230: , Brobeil A, Cruse CW, Messina JL, et al: Cost analysis of sentinel lymph node biopsy as an alternative to elective lymph node dissection in patients with malignant melanoma. Surg Oncol Clin N Am 8: , Wrightson WR, Reintgen DS, Edwards MJ, et al: Morbidity of sentinel lymph node biopsy for melanoma. Abstract presented at the Society of Surgical Oncology, March 15-18, 2001, Washington, DC 18. Veronesi U, Adamus J, Bandiera DC, et al: Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities. Cancer 49: , Sim FH, Taylor WF, Ivins JC, et al: A prospective randomized study of the efficacy of routine elective lymphadenectomy in management of malignant melanoma. Cancer 41: , Cascinelli N, Morabito A, Santinami M, et al: Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: A randomized trial WHO Melanoma Programme. Lancet 351: , Balch CM, Soong S-J, Bartolucci AA, et al: Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg 224: , Balch CM, Soong S, Ross MI, et al: Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm): Intergroup Melanoma Surgical Trial. Ann Surg Oncol : Reintgen DS: Emerging evidence for a survival benefit associated with regional lymph node dissection for melanoma. Ann Surg Oncol 7:75-76, Reintgen DS: Regional nodal surgery for melanoma impacts recurrence rates and survival. Ann Surg Oncol 7:80-81, Kirkwood JM, Strawderman MH, Ernstoff MS, et al: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST J Clin Oncol 14:7-17, Kirkwood JM, Ibrahim J, Sondak V, et al: High- and low-dose interferon alpha-2b in high-risk melanoma: First analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 18: , Buzaid AC, Ross MI, Balch CM, et al: Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. J Clin Oncol 15: , Balch CM, Buzaid AC, Atkins MB, et al: A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer 88: , 2000
ORIGINAL ARTICLE. Clinical Node-Negative Thick Melanoma
ORIGINAL ARTICLE Clinical Node-Negative Thick Melanoma George I. Salti, MD; Ashwin Kansagra, MD; Michael A. Warso, MD; Salve G. Ronan, MD ; Tapas K. Das Gupta, MD, PhD, DSc Background: Patients with T4
More informationNodal staging in localized melanoma. The experience of the Brescia Melanoma Unit
The British Association of Plastic Surgeons (2003) 56, 534 539 Nodal staging in localized melanoma. The experience of the Brescia Melanoma Unit Giorgio Manca a, *, Fabio Facchetti b, Claudio Pizzocaro
More informationRebecca Vogel, PGY-4 March 5, 2012
Rebecca Vogel, PGY-4 March 5, 2012 Historical Perspective Changes In The Staging System Studies That Started The Talk Where We Go From Here Cutaneous melanoma has become an increasingly growing problem,
More informationPatient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival
MOLECULAR AND CLINICAL ONCOLOGY 7: 1083-1088, 2017 Patient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival FARUK TAS
More informationPAPER. Prognostic Information From Sentinel Lymph Node Biopsy in Patients With Thick Melanoma
PAPER Prognostic Information From Sentinel Lymph Node Biopsy in Patients With Thick Melanoma Charles R. Scoggins, MD, MBA; Adrianne L. Bowen, MD; Robert C. Martin II, MD, PhD; Michael J. Edwards, MD; Douglas
More informationTalk to Your Doctor. Fact Sheet
Talk to Your Doctor Hearing the words you have skin cancer is overwhelming and would leave anyone with a lot of questions. If you have been diagnosed with Stage I or II cutaneous melanoma with no apparent
More informationClinical Practice Guidelines
Clinical Practice Guidelines Clinical Practice Guidelines for Melanoma Douglas Reintgen, MD, et al H. Lee Moffitt Cancer Center & Research Institute These clinical practice guidelines for melanoma have
More informationNo Benefit to Routine Completion Lymphadenectomy for Sentinel Lymph Node Positive Melanoma
No Benefit to Routine Completion Lymphadenectomy for Sentinel Lymph Node Positive Melanoma Michael Lowe, MD Assistant Professor of Surgery Winship Cancer Institute Emory University School of Medicine July
More informationRecent Advances in Melanoma Staging and Therapy
Annals of Surgical Oncology, 6(5):467 475 Published by Lippincott Williams & Wilkins 1999 The Society of Surgical Oncology, Inc. Recent Advances in Melanoma Staging and Therapy Kelly M. McMasters, MD,
More informationSurgical Issues in Melanoma
Surgical Issues in Melanoma Mark B. Faries, MD, FACS Director, Donald L. Morton Melanoma Research Program Director, Surgical Oncology Training Program Professor of Surgery John Wayne Cancer Institute Surgical
More informationIs There a Benefit to Sentinel Lymph Node Biopsy in Patients With T4 Melanoma?
Is There a Benefit to Sentinel Lymph Node Biopsy in atients With T4 Melanoma? Csaba Gajdos, MD 1 ; Kent A. Griffith, MH, MS 2 ; Sandra L. Wong, MD 1 ; Timothy M. Johnson, MD 1,3 ; Alfred E. Chang, MD 1
More informationPAPER. Is Completion Lymphadenectomy After a Positive Sentinel Lymph Node Biopsy for Cutaneous Melanoma Always Necessary?
PAPER Is Completion Lymphadenectomy After a Positive Sentinel Lymph Node Biopsy for Cutaneous Melanoma Always Necessary? Nahel Elias, MD; Kenneth K. Tanabe, MD; Arthur J. Sober, MD; Michele A. Gadd, MD;
More informationTranslating Evidence into Practice: Primary Cutaneous Melanoma Guidelines. Sentinel Lymph Node Biopsy
American Academy of Dermatology 2018 Annual Meeting San Diego, CA, February 17, 2018 Translating Evidence into Practice: Primary Cutaneous Melanoma Guidelines. Sentinel Lymph Node Biopsy Christopher Bichakjian,
More informationCutaneous Melanoma: Epidemiology (USA) The Sentinel Node in Head and Neck Melanoma. Cutaneous Melanoma: Epidemiology (USA)
The Sentinel Node in Head and Neck Melanoma Cutaneous Melanoma: Epidemiology (USA) 6 th leading cause of cancer among men and women 68,720 new cases of invasive melanoma in 2009 8,650 deaths from melanoma
More informationSentinel Lymph Node Biopsy for Melanoma: Indications and Rationale
Sentinel lymph node biopsy is recommended for most patients with melanomas 0.76 mm and for all good surgical candidates with melanomas 1.0 mm. Catherine Hickson. Figs in Alizarin Crimson. Oil on Belgian
More informationAbstract. Background We evaluated the contribution of sentinel-node biopsy to outcomes in patients with newly diagnosed melanoma.
The new england journal of medicine established in 112 september 2, 6 vol. 355 no. 13 Sentinel-Node Biopsy or Nodal in Melanoma Donald L. Morton, M.D., John F. Thompson, M.D., Alistair J. Cochran, M.D.,
More informationDesmoplastic Melanoma: Surgical Management and Adjuvant Therapy
Desmoplastic Melanoma: Surgical Management and Adjuvant Therapy Dale Han, MD Assistant Professor Department of Surgery Section of Surgical Oncology No disclosures Background Desmoplastic melanoma (DM)
More informationFive years of sentinel node biopsy for melanoma: the St George s Melanoma Unit experience
The British Association of Plastic Surgeons (2004) 57, 97 104 Five years of sentinel node biopsy for melanoma: the St George s Melanoma Unit experience Adam Topping a, *, Donald Dewar a, Victoria Rose
More informationORIGINAL ARTICLE PROGNOSTIC IMPLICATION OF SENTINEL LYMPH NODE BIOPSY IN CUTANEOUS HEAD AND NECK MELANOMA
ORIGINAL ARTICLE PROGNOSTIC IMPLICATION OF SENTINEL LYMPH NODE BIOPSY IN CUTANEOUS HEAD AND NECK MELANOMA Benjamin E. Saltman, MD, 1 Ian Ganly, MD, 2 Snehal G. Patel, MD, 2 Daniel G. Coit, MD, 3 Mary Sue
More informationMolecular Enhancement of Sentinel Node Evaluation
Cochran Illustrations 060104 Molecular Enhancement of Sentinel Node Evaluation Alistair Cochran, MD and Rong Huang MD Departments of Pathology and Laboratory Medicine and Surgery, David Geffen School of
More information1
www.clinicaloncology.com.ua 1 Prognostic factors of appearing micrometastases in sentinel lymph nodes in skin melanoma M.N.Kukushkina, S.I.Korovin, O.I.Solodyannikova, G.G.Sukach, A.Yu.Palivets, A.N.Potorocha,
More informationSentinel Lymph Node Biopsy Is Valuable For All Cancer. Surgery Grand Rounds Debate October 6, 2008 Joel Baumgartner
Sentinel Lymph Node Biopsy Is Valuable For All Cancer Surgery Grand Rounds Debate October 6, 2008 Joel Baumgartner History Lymphatics first described by Rasmus Bartholin in 1653 Rudolf Virchow postulated
More informationMelanoma Surgery Update James R. Ouellette, DO FACS Premier Health Cancer Institute Wright State University Chief, Surgical Oncology Division
Melanoma Surgery Update 2018 James R. Ouellette, DO FACS Premier Health Cancer Institute Wright State University Chief, Surgical Oncology Division Surgery for Melanoma Mainstay of treatment for potentially
More informationUpdate on SLN and Melanoma: DECOG and MSLT-II. Gordon H. Hafner, MD, FACS
Update on SLN and Melanoma: DECOG and MSLT-II Gordon H. Hafner, MD, FACS No disclosures The surgery of malignant disease is not the surgery of organs, it is of the lymphatic system. Lord Moynihan Lymph
More informationPatent Blue Dye (P.B.D) tums.ac.ir
80-84 1387 2 66 80 : 30 :.. 1385 1382.. Patent Blue Dye (P.B.D). 48 :. - (%47)13 19 195 17.. :.. : * * 88723410 : email: omranipour@ tums.ac.ir. 4 5. Patent Blue Dye (P.B.D) 6-8 %13. %20 1 2. 3 1992 Morton.
More informationMelanoma Quality Reporting
Melanoma Quality Reporting September 1, 2013 December 31, 2016 Laurence McCahill, MD Surgical Oncologist Metro Health Surgical Oncology Metro Health Professional Building 2122 Health Drive SW Wyoming,
More informationSentinel Lymph Node Biopsy for Head and Neck Cutaneous Melanoma
Sentinel Lymph Node Biopsy for Head and Neck Cutaneous Melanoma S. Ross Patton, MD - PGY III Faculty Mentor: Susan McCammon, MD The University of Texas Medical Branch (UTMB Health) Department of Otolaryngology
More informationNodal Treatment in Melanoma: Snow to MSLT-II
Nodal Treatment in Melanoma: Snow to MSLT-II Mark B. Faries, MD, FACS Director, Donald L. Morton Melanoma Research Program Program Director, JWCI Complex General Surgical Oncology Fellowship Director,
More informationTherapeutic Lymph Node Dissection in Melanoma: Different Prognosis for Different Macrometastasis Sites?
Ann Surg Oncol (01) 19:91 91 DOI.14/s44-01-401- ORIGINAL ARTICLE MELANOMAS Therapeutic Lymph Node Dissection in Melanoma: Different Prognosis for Different Macrometastasis Sites? K. P. Wevers, MD, E. Bastiaannet,
More informationJ Clin Oncol 34: by American Society of Clinical Oncology INTRODUCTION
VOLUME 34 NUMBER 10 APRIL 1, 2016 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Final Results of the Sunbelt Melanoma Trial: A Multi-Institutional Prospective Randomized Phase III Study Evaluating
More informationORIGINAL ARTICLE. Cervical Sentinel Lymph Node Biopsy for Melanomas of the Head and Neck and Upper Thorax
ORIGINAL ARTICLE Cervical Sentinel Lymph Node Biopsy for Melanomas of the Head and Neck and Upper Thorax Jeffrey D. Wagner, MD; Hee-Myung Park, MD; John J. Coleman III, MD; Charlene Love, RN; John T. Hayes,
More informationMorphological characteristics of the primary tumor and micrometastases in sentinel lymph nodes as a predictor of melanoma progression
Morphological characteristics of the primary tumor and micrometastases in sentinel lymph nodes as a predictor of melanoma progression M.N. Kukushkina, S.I. Korovin, O.I. Solodyannikova, G.G. Sukach, A.Yu.
More informationAn estimated 76,690 patients will be diagnosed with invasive
SONDAK ET AL Evidence-Based Clinical Practice Guidelines on the Use of Sentinel Lymph Node Biopsy in Melanoma Vernon K. Sondak, MD, Sandra L. Wong, MD, Jeffrey E. Gershenwald, MD, and John F. Thompson,
More informationIncreasing Age Is Associated with Worse Prognostic Factors and Increased Distant Recurrences despite Fewer Sentinel Lymph Node Positives in Melanoma
Increasing Age Is Associated with Worse Prognostic Factors and Increased Distant Recurrences despite Fewer Sentinel Lymph Node Positives in Melanoma A. J. Page, Emory University A. Li, Emory University
More informationSentinel Lymph Node Biopsies in Cutaneous Melanoma: A systematic review of the literature. Sasha Jenkins
Sentinel Lymph Node Biopsies in Cutaneous Melanoma: A systematic review of the literature By Sasha Jenkins A Master s Paper submitted to the faculty of the University of North Carolina at Chapel Hill in
More informationSentinel Lymph Node Biopsy: Past and Present Implications for the Management of Cutaneous Melanoma with Nodal Metastasis
American Journal of Clinical Dermatology (2018) 19 (Suppl 1):S24 S30 https://doi.org/10.1007/s40257-018-0379-0 REVIEW ARTICLE Sentinel Lymph Node Biopsy: Past and Present Implications for the Management
More informationSentinel Node in Malignant Melanoma The Pathologist s Point of View
Sentinel Node in Malignant Melanoma The Pathologist s Point of View S.J. Diaz-Cano Department of Pathology, Barts and The London School of Medicine, University of London, Barts and The London NHS Trust,
More informationNEW SURGICAL APPROACHES TO MELANOMA THERAPY
NEW SURGICAL APPROACHES TO MELANOMA THERAPY Melanoma 2003: New Insights Into Therapy & Treatment Douglas L. Fraker, M.D. University of Pennsylvania Surgical Treatment of Melanoma Primary resection margins
More informationLymph node ratio is an important and independent prognostic factor for patients with stage III melanoma.
Thomas Jefferson University Jefferson Digital Commons Department of Surgery Faculty Papers Department of Surgery 1-1-2012 Lymph node ratio is an important and independent prognostic factor for patients
More informationPrognosis of Sentinel Node Staged Patients with Primary Cutaneous Melanoma
Prognosis of Sentinel Node Staged Patients with Primary Cutaneous Melanoma Otmar Elsaeßer 1., Ulrike Leiter 1 *., Petra G. Buettner 2, Thomas K. Eigentler 1, Friedegund Meier 1, Benjamin Weide 1, Gisela
More informationPosition Statement on Management of the Axilla in Patients with Invasive Breast Cancer
- Official Statement - Position Statement on Management of the Axilla in Patients with Invasive Breast Cancer Sentinel lymph node (SLN) biopsy has replaced axillary lymph node dissection (ALND) for the
More informationMalignant Melanoma in Turkey: A Single Institution s Experience on 475 Cases
Malignant Melanoma in Turkey: A Single Institution s Experience on 475 Cases Faruk Tas, Sidika Kurul, Hakan Camlica and Erkan Topuz Institute of Oncology, Istanbul University, Istanbul, Turkey Received
More informationThin Melanoma with Nodal Involvement: Analysis of Demographic, Pathologic, and Treatment Factors with Regard to Prognosis
Ann Surg Oncol DOI 10.1245/s10434-016-5646-9 ORIGINAL ARTICLE MELANOMAS Thin Melanoma with Nodal Involvement: Analysis of Demographic, Pathologic, and Treatment Factors with Regard to Prognosis Giorgos
More informationORIGINAL ARTICLE. Reliability of Sentinel Lymph Node Mapping With Biopsy for Head and Neck Cutaneous Melanoma
ORIGINAL ARTICLE Reliability of Sentinel Lymph Node Mapping With Biopsy for Head and Neck Cutaneous Melanoma Cecelia E. Schmalbach, MD; Brian Nussenbaum, MD; Riley S. Rees, MD; Jennifer Schwartz, MD; Timothy
More informationCitation for published version (APA): Francken, A. B. (2007). Primary and metastatic melanoma: aspects of follow-up and staging s.n.
University of Groningen Primary and metastatic melanoma Francken, Anne Brecht IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check
More informationDisclosures. SLNB for Melanoma 25/02/2014 SENTINEL LYMPH NODE BIOPSY FOR MELANOMA: CURRENT GUIDELINES AND THEIR CLINICAL APPLICATION
8 th Canadian Melanoma Conference February 22, 2014 Rimrock Resort Hotel, Banff, Alberta SENTINEL LYMPH NODE BIOPSY FOR MELANOMA: CURRENT GUIDELINES AND THEIR CLINICAL APPLICATION Christopher Bichakjian,
More informationLYMPHATIC DRAINAGE PATTERNS OF HEAD AND NECK CUTANEOUS MELANOMA OBSERVED ON LYMPHOSCINTIGRAPHY AND SENTINEL LYMPH NODE BIOPSY
LYMPHATIC DRAINAGE PATTERNS OF HEAD AND NECK CUTANEOUS MELANOMA OBSERVED ON LYMPHOSCINTIGRAPHY AND SENTINEL LYMPH NODE BIOPSY Doris Lin, MD, 1 Benjamin L. Franc, MD, 2 Mohammed Kashani-Sabet, MD, 3 Mark
More informationContradiction of Clinical Expectations in Lymphoscintigraphy Sentinel Node Mapping in Detecting Microscopic Melanoma Metastasis
Case Report 474 Contradiction of Clinical Expectations in Lymphoscintigraphy Sentinel Node Mapping in Detecting Microscopic Melanoma Metastasis John WC Chang, MD; Hsui-Fong Chiang, RN; Yung-Feng Lo 1,
More informationAnalysis of Lymph Nodal Metastases in Malignant Melanoma Using the Poisson Probability Paradigm and Bayes Rule
Anatomic Pathology / POISSON PARADIGM AND METASTATIC MELANOMA Analysis of Lymph Nodal Metastases in Malignant Melanoma Using the Poisson Probability Paradigm and Bayes Rule Robin T. Vollmer, MD Key Words:
More informationEpithelial Cancer- NMSC & Melanoma
Epithelial Cancer- NMSC & Melanoma David Chin MB, BCh, BAO, LRCP, LRCS (Ireland) MCh(MD), PhD (UQ), FRCS, FRACS (Plast) Plastic & Reconstructive Surgeon Visiting Scientist Melanoma Genomic Group & Drug
More informationSentinel Lymph Node Biopsy for Breast Cancer
Sentinel Lymph Node Biopsy for Breast Cancer Registrar Tutorial Adam Cichowitz Surgical Registrar The Royal Melbourne Hospital Sentinel Lymph Node Biopsy Axillary LN status important prognostic factor
More informationTopics for Discussion. Malignant Melanoma. Surgical Treatment. Current Treatment of Cutaneous Melanoma 5/17/2013. Lymph Regional nodes:
Topics for Discussion What is a sentinel lymph node (SLN)? Utility of sentinel lymph biopsies: therapeutic or staging? Current Treatment of Cutaneous Melanoma Carlos Corvera, M.D. Associate Professor of
More informationControversies and Questions in the Surgical Treatment of Melanoma
Controversies and Questions in the Surgical Treatment of Melanoma Giorgos C. Karakousis, M.D. Assistant Professor of Surgery Division of Endocrine and Oncologic Surgery University of Pennsylvania School
More informationWhat Is a Sentinel Node? Re-Evaluating the 10% Rule for Sentinel Lymph Node Biopsy in Melanoma
Journal of Surgical Oncology 2007;95:623 628 What Is a Sentinel Node? Re-Evaluating the 10% Rule for Sentinel Lymph Node Biopsy in Melanoma HIDDE M. KROON, MD, 1 LORI LOWE, MD, 2 SANDRA WONG, MD, 1 DOUG
More informationPatients with thick cutaneous melanoma ( 4 mm) pose a challenge. Prognostic Factors in Patients with Thick Cutaneous Melanoma (> 4 mm)
1049 Prognostic Factors in Patients with Thick Cutaneous Melanoma (> 4 mm) Elizabeth Zettersten, M.D. 1 Richard W. Sagebiel, M.D. 1 James R. Miller III, Ph.D. 1,2 Sreedhar Tallapureddy, M.D. 1 Stanley
More informationSentinel Lymph Node Biopsy: Current Evidence for its Role in Managing Melanoma
Sentinel Lymph Node Biopsy: Current Evidence for its Role in Managing Melanoma John A Zitelli MD Adjunct Clinical Associate Professor Dermatology, Otolaryngology, Plastic Surgery University of Pittsburgh
More informationABSTRACT. Background Sentinel-node biopsy, a minimally invasive procedure for regional melanoma staging, was evaluated in a phase 3 trial.
The new england journal of medicine established in 1812 february 13, 214 vol. 37 no. 7 Final Trial Report of Sentinel-Node Biopsy versus Nodal Observation in Melanoma D.L. Morton, J.F. Thompson, A.J. Cochran,
More informationMelanoma of the Skin INTRODUCTION SUMMARY OF CHANGES
24 Melanoma of the Skin C44.0 Skin of lip, NOS C44.1 Eyelid C44.2 External ear C44.3 Skin of other and unspecified parts of face C44.4 Skin of scalp and neck C44.5 Skin of trunk C44.6 Skin of upper limb
More informationMELANOMA LETTER. Surgical Treatment of Primary Melanoma: Where Do We Stand After MSLT-II? THE. From the Editors MSLT-II. SkinCancer.
THE MELANOMA LETTER A PUBLICATION OF THE SKIN CANCER FOUNDATION DEBORAH S. SARNOFF, MD, President WINTER 2017, Vol. 35 DAN LATORE, Executive Director Surgical Treatment of Primary Melanoma: Where Do We
More informationPAPER. Importance of Sentinel Lymph Node Biopsy in Patients With Thin Melanoma
PAPER Importance of Sentinel Lymph Node Biopsy in Patients With Thin Melanoma Byron E. Wright, MD; Randall P. Scheri, MD; Xing Ye, MS; Mark B. Faries, MD; Roderick R. Turner, MD; Richard Essner, MD; Donald
More informationResults, morbidity, and quality of life of melanoma patients undergoing sentinel lymph node staging Vries, Mattijs de
University of Groningen Results, morbidity, and quality of life of melanoma patients undergoing sentinel lymph node staging Vries, Mattijs de IMPORTANT NOTE: You are advised to consult the publisher's
More informationMelanoma of the Skin
24 Melanoma of the Skin C44.0 Skin of lip, NOS C44.1 Eyelid C44.2 External ear C44.3 Skin of other and unspecified parts of face C44.4 Skin of scalp and neck C44.5 Skin of trunk C44. Skin of upper limb
More informationWho is the Ideal Candidate for PEG Intron?
Who is the Ideal Candidate for PEG Intron? Sanjiv S. Agarwala, MD Chief, Oncology & Hematology St. Luke s Cancer Center Professor, Temple University School of Medicine Philadelphia, PA, USA Overview Introduction
More informationORIGINAL ARTICLE. Linh Lam, MD; Edward Krementz, MD; Clifton McGinness, MD; Richard Godfrey, MD
Melanoma of the Clavicular Region Multimodal Treatment ORIGINAL ARTICLE Linh Lam, MD; Edward Krementz, MD; Clifton McGinness, MD; Richard Godfrey, MD Hypothesis: Treatment for melanoma that has metastasized
More informationNCCN Guidelines for Cutaneous Melanoma V Meeting on 06/20/18
ME-1, ME-3, ME-B Submission from Castle Biosciences, Inc (05/30/18) to consider inclusion of the DecisionDx-Melanoma test in the guidelines as a prognostic test that provides stratification according to
More informationUniversity of Groningen
University of Groningen Nodular Histologic Subtype and Ulceration are Tumor Factors Associated with High Risk of Recurrence in Sentinel Node-Negative Melanoma Patients Faut, Marloes; Wevers, Kevin; van
More informationClinical Pathological Conference. Malignant Melanoma of the Vulva
Clinical Pathological Conference Malignant Melanoma of the Vulva History F/48 Chinese Married Para 1 Presented in September 2004 Vulval mass for 2 months Associated with watery and blood stained discharge
More informationORIGINAL ARTICLE. Patterns of Recurrence in Patients With Melanoma After Radical Lymph Node Dissection
ORIGINAL ARTICLE Patterns of Recurrence in Patients With Melanoma After Radical Lymph Node Dissection Nir Nathansohn, MD, MHA; Jacob Schachter, MD; Haim Gutman, MD Hypothesis: Previous interventions (excisional
More informationPAPER. Effect of Multiple Nodal Basin Drainage on Cutaneous Melanoma
PAPER Effect of Multiple Nodal Basin Drainage on Cutaneous Melanoma Andrea C. Federico, BA; Anees B. Chagpar, MD; Merrick I. Ross, MD; Robert C. G. Martin, MD; R. Dirk Noyes, MD; James S. Goydos, MD; Peter
More informationORIGINAL ARTICLE. (SLN) biopsy is revolutionizing
ORIGINAL ARTICLE Management of Malignant Melanoma of the Head and Neck Using Dynamic Lymphoscintigraphy and Gamma Probe Guided Sentinel Lymph Node Biopsy Grant W. Carlson, MD; Douglas R. Murray, MD; Robert
More informationQuality ID #397: Melanoma Reporting National Quality Strategy Domain: Communication and Care Coordination
Quality ID #397: Melanoma Reporting National Quality Strategy Domain: Communication and Care Coordination 2018 OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS ONLY MEASURE TYPE: Outcome DESCRIPTION: Pathology
More informationCOMPARATIVE ANALYSIS OF COLON AND RECTAL CANCERS IN SENTINEL LYMPH NODE MAPPING
Trakia Journal of Sciences, Vol. 5, No. 1, pp 10-14, 2007 Copyright 2007 Trakia University Available online at: http://www.uni-sz.bg ISSN 1312-1723 Original Contribution COMPARATIVE ANALYSIS OF COLON AND
More informationLessons Learned From the Sunbelt Melanoma Trial
Journal of Surgical Oncology 2004;86:212 223 Lessons Learned From the Sunbelt Melanoma Trial KELLY M. McMASTERS, MD, PhD, 1 * R. DIRK NOYES, MD, 2 DOUGLAS S. REINTGEN, MD, 3 JAMES S. GOYDOS, MD, 4 PETER
More informationCase : A 49-Year-Old Woman with a Pigmented Lesion on the Arm
T h e n e w e ng l a nd j o u r na l o f m e dic i n e case records of the massachusetts general hospital Founded by Richard C. Cabot Nancy Lee Harris, m.d., Editor Eric S. Rosenberg, m.d., Associate Editor
More informationSentinel lymph node (SLN) biopsy is a wellestablished
ORIGINAL ARTICLE DISCORDANT LYMPHATIC DRAINAGE PATTERNS REVEALED BY SERIAL LYMPHOSCINTIGRAPHY IN CUTANEOUS HEAD AND NECK MALIGNANCIES Alliric I. Willis, MD, John A. Ridge, MD, PhD Department of Surgical
More informationPredictive Factors for the Positivity of the Sentinel Lymph Node in Malignant Melanoma
ORIGINAL RESEARCH SURGERY // ANATOMO-PATHOLOGY Predictive Factors for the Positivity of the Sentinel Lymph Node in Malignant Melanoma Călin Crăciun, Orsolya Hankó- Bauer, Zalán Benedek, Sorin Sorlea, Marius
More informationSentinel Lymph Node Biopsy for the T1 (Thin) Melanoma: Is It Necessary?
Sentinel Lymph Node Biopsy for the T1 (Thin) Melanoma: Is It Necessary? Maurice Y. Nahabedian, MD Anthony P. Tufaro, MD Paul N. Manson, MD The use of sentinel lymph node biopsy for the T1 melanoma is controversial.
More informationNIH Public Access Author Manuscript J Surg Oncol. Author manuscript; available in PMC 2012 August 1.
NIH Public Access Author Manuscript Published in final edited form as: J Surg Oncol. 2011 August 1; 104(2): 111 115. doi:10.1002/jso.21903. Does metastasectomy improve survival in patients with Stage IV
More information16/09/2015. ACOSOG Z011 changing practice. Presentation outline. Nodal mets #1 prognostic tool. Less surgery no change in oncologic outcomes
ACOSOG Z011 changing practice The end of axillary US/FNA? Preoperative staging of the axilla in the era of Z011 Adena S Scheer MD MSc FRCSC Surgical Oncologist, St. Michael s Hospital Assistant Professor,
More informationImpact of Prognostic Factors
Melanoma Prognostic Factors: where we started, where are we going? Impact of Prognostic Factors Staging Management Surgical intervention Adjuvant treatment Suraj Venna, MD Assistant Clinical Professor,
More informationWork-up/Follow-up: Baseline and Surveillance Studies for Cutaneous Melanoma Patients
2018 AAD Annual Meeting, San Diego, CA Work-up/Follow-up: Baseline and Surveillance Studies for Cutaneous Melanoma Patients Susan M. Swetter, MD, FAAD Professor of Dermatology Director, Pigmented Lesion
More informationCanadian Scientific Journal. Intraoperative color detection of lymph nodes metastases in thyroid cancer
Canadian Scientific Journal 2 (2014) Contents lists available at Canadian Scientific Journal Canadian Scientific Journal journal homepage: Intraoperative color detection of lymph nodes metastases in thyroid
More informationPrinted by Martina Huckova on 10/3/2011 3:04:54 PM. For personal use only. Not approved for distribution. Copyright 2011 National Comprehensive
Table of Contents NCCN Categories of Evidence and Consensus Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate. Category 2A: Based upon lower-level
More informationSLN Mapping in Cervical Cancer. Memorial Sloan Kettering Cancer Center New York, USA
Lead Grou p Log SLN Mapping in Cervical Cancer Nadeem R. Abu-Rustum, M.D. Memorial Sloan Kettering Cancer Center New York, USA Conflict of Interest Disclosure Nadeem R. Abu-Rustum, M.D. I have no financial
More informationClinical utilities and biological characteristics of melanoma sentinel lymph nodes
W J C O World Journal of Clinical Oncology Submit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.5306/wjco.v7.i2.174 World J Clin Oncol 2016 April
More informationRadionuclide detection of sentinel lymph node
Radionuclide detection of sentinel lymph node Sophia I. Koukouraki Assoc. Professor Department of Nuclear Medicine Medicine School, University of Crete 1 BACKGROUND The prognosis of malignant disease is
More informationResults of the ACOSOG Z0011 Trial
DCIS and Early Breast Cancer Symposium JUNE 15-17 2012 CAPPADOCIA Results of the ACOSOG Z0011 Trial Kelly K. Hunt, M.D. Professor of Surgery Axillary Node Dissection Staging, Regional control, Survival
More informationSentinel Lymph Node Biopsy in Patients With Thin Melanoma
STUDY Sentinel Lymph Node Biopsy in Patients With Thin Melanoma Julie B. Lowe, MD; Eva Hurst, MD; Jeffrey F. Moley, MD; Lynn A. Cornelius, MD Objective: To define the percentage of positive sentinel lymph
More informationJournal of IMAB - Annual Proceeding (Scientific Papers) 2007, vol. 13, book 1
Journal of IMAB - Annual Proceeding (Scientific Papers) 2007, vol. 13, book 1 COMPARATIVE ANALYSIS OF ENDOSCOPICALY SUBMUCOSAL VS. OPEN SURGERY SUB- SEROSAL APPLICATION PATENT BLUE V INTRAOPERATIVE METHOD
More informationSentinel Node Alphabet Soup: MSLT-1, DeCOG-SLT, MSLT-2, UNC
Sentinel Node Alphabet Soup: MSLT-1, DeCOG-SLT, MSLT-2, UNC David W. Ollila MD James and Jesse Millis Professor of Surgery University of North Carolina, Chapel Hill Disclosures: None July 15, 2018 AJCC
More informationMelanoma Patients and the Sentinel Lymph Node (SLN) Procedure: An Oncologic Surgeon s Perspective
Melanoma Patients and the Sentinel Lymph Node (SLN) Procedure: An Oncologic Surgeon s Perspective Giorgos C. Karakousis, M.D. Associate Professor of Surgery Hospital of the University of Pennsylvania Disclosures
More informationUpdates on Melanoma: Are You Following the Latest Guidelines of Care? Jerry Brewer, MD
Updates on Melanoma: Are You Following the Latest Guidelines of Care? Jerry Brewer, MD Disclosure Statement Update on Melanoma Are You Following the Latest Guidelines of Care? I, Jerry D. Brewer, MD, do
More informationJ Clin Oncol 27: by American Society of Clinical Oncology INTRODUCTION
VOLUME 27 NUMBER 36 DECEMBER 2 29 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T From Johns Hopkins Medical Institutions, Baltimore, MD; The University of Texas M. D. Anderson Cancer Center,
More informationSentinel Lymph Node Status is the Most Important Prognostic Factor in Patients With Melanoma of the Scalp
The Laryngoscope VC 2013 The American Laryngological, Rhinological and Otological Society, Inc. Sentinel Lymph Node Status is the Most Important Prognostic Factor in Patients With Melanoma of the Scalp
More informationMichael T. Tetzlaff MD, PhD
American Joint Cancer Committee (AJCC) staging system for primary cutaneous melanoma (8 th Edition) and principles of sentinel lymph node evaluation Emphasis on concise and accurate reporting of primary
More informationMeasure #397: Melanoma Reporting National Quality Strategy Domain: Communication and Care Coordination
Measure #397: Melanoma Reporting National Quality Strategy Domain: Communication and Care Coordination 2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Outcome DESCRIPTION: Pathology reports
More informationManagement of the patient with Lymph Node Involvement. Michael A Henderson Peter MacCallum Cancer Center Univ of Melbourne
Management of the patient with Lymph Node Involvement Michael A Henderson Peter MacCallum Cancer Center Univ of Melbourne Lymph Node Field Recurrence Most important prognostic factor for early stage melanoma
More informationTumor Mitotic Rate Added to the Equation: Melanoma Prognostic Factors Changed?
Ann Surg Oncol (2015) 22:2978 2987 DOI 10.1245/s10434-014-4349-3 ORIGINAL ARTICLE MELANOMAS Tumor Mitotic Rate Added to the Equation: Melanoma Prognostic Factors Changed? A Single-Institution Database
More informationis time consuming and expensive. An intra-operative assessment is not going to be helpful if there is no more tissue that can be taken to improve the
My name is Barry Feig. I am a Professor of Surgical Oncology at The University of Texas MD Anderson Cancer Center in Houston, Texas. I am going to talk to you today about the role for surgery in the treatment
More information